Elranatamab for multiple myeloma that has come back
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your multiple myeloma has come back or stopped responding to at least 3 different types of treatment (like lenalidomide, bortezomib, and daratumumab)
- You have measurable disease (such as M-protein in your blood or urine) that can be tracked
- You have not had a treatment that targets BCMA before
- You are able to stay within an hour's drive of the trial hospital and have a caregiver with you for the first 9 days after your first dose
- You do not have serious heart problems, nerve damage, or another active cancer (except some skin cancers)
- You are 18 or older and able to care for yourself (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to treatment, specifically after they have received a therapy named idecabtagene vicleucel (Abecma). It aims to see if elranatamab can help control the disease.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
Hear when a new Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.